Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Background:

• Multiple myeloma is a hematologic malignancy characterized by uncontrolled proliferation of plasma cells.
• Relapsed/refractory multiple myeloma (RRMM) presents a significant unmet medical need due to limited treatment options and poor prognosis.

Purpose of the Study:

• To evaluate the safety and efficacy of linvoseltamab, a novel B-cell maturation antigen (BCMA) × CD3 bispecific antibody, in patients with RRMM.
• To determine the optimal dose of linvoseltamab (50 mg vs. 200 mg) in a first-in-human Phase I/II trial.

Main Methods:

• A Phase I/II, first-in-human, open-label trial enrolled patients with RRMM.
• Patients received escalating doses of linvoseltamab (50 mg or 200 mg).
• The primary endpoint in Phase II was the overall response rate (ORR).

Main Results:

• The 200 mg dose of linvoseltamab achieved a 71% ORR, with 50% of patients achieving a complete response or better.
• The median duration of response (DOR) for the 200 mg dose was 29.4 months.
• Common adverse events included cytokine release syndrome, neutropenia, and anemia; immune effector cell-associated neurotoxicity syndrome occurred in 7.7% of patients.

Conclusions:

• Linvoseltamab 200 mg demonstrated deep and durable responses in patients with RRMM.
• The drug exhibited an acceptable safety profile, with manageable adverse events.
• Linvoseltamab represents a promising therapeutic option for patients with RRMM.